analyzeportfolio
NYSE · Healthcare

3M CO (MMM)

As-reported financials and SEC filings for 3M CO. The latest annual period is FY2025. The latest reported quarter is Q2 FY2026. Financial statements come straight from the company’s EDGAR filings; valuation figures such as P/E and market cap use market data.

About 3M CO

3M Company is a diversified technology firm operating globally in three main segments: Safety and Industrial, Transportation and Electronics, and Consumer. It manufactures a wide range of products including abrasives, adhesives, personal safety equipment, electronic materials, home care items, and office supplies. The company serves various markets such as industrial, automotive, aerospace, electronics, and consumer goods through multiple distribution channels worldwide.

Snapshot

Revenue
$24.95B
Revenue growth (YoY)
1.5%
Net income
$3.25B
Diluted EPS
$6.00
Gross margin
39.9%
Operating margin
18.6%
Net margin
13.0%
FCF margin
5.6%
ROE
68.5%
net income / fiscal-year-end equity
P/E
30.2×
trailing when available, otherwise FY EPS
Market cap
$87.80B
Long-term debt / equity
2.30×
non-current term debt only

Fundamentals are from SEC filings for FY2025, the latest annual period (ended December 31, 2025). P/E and market cap are derived from stored market prices, last retrieved on a rolling basis and typically within the past week.

What changed at 3m

  • Revenue grew 1.5% to $24.9B in FY2025, after a 0.1% decline the year before.
  • Operating margin is 18.6% in FY2025, -2.3 pp against 20.8% in FY2021.
  • Most recent quarter Q2 FY2026: revenue $6.5B, up 2.5% from Q2 FY2025.
  • Free cash flow was $1.4B in FY2025, 5.6% of revenue.
  • Net income fell 22.1% to $3.3B in FY2025.

Computed from the as-reported figures in the statements below. A change we cannot state from filed figures is left out rather than estimated.

Peer comparison

Where 3m’s fundamentals sit among the 88 medical device companies. Each figure is ranked only against peers that report it, from lowest (left) to highest (right).

Gross margin39.9%
17th percentile of 77
Operating margin18.6%
89th percentile of 80
Net margin13.0%
84th percentile of 81
FCF margin5.6%
66th percentile of 74
Revenue growth (YoY)+1.5%
23rd percentile of 87
ROE68.5%
97th percentile of 79
P/E30.2×
55th percentile of 32
Long-term debt / equity2.30×
85th percentile of 54
Short interest3.72d
55th percentile of 88

3m’s return on equity of 68.5% ranks in the 97th percentile of the 79 medical device companies reporting it. 3m’s operating margin of 18.6% ranks in the 89th percentile of the 80 medical device companies reporting it. 3m’s long-term debt to equity of 2.30 ranks in the 85th percentile of the 54 medical device companies reporting it.

No reported insider purchases (code P) in the last 90 days; 5 insider sales totaling $4.3M. For context, about 15% of companies in the universe saw any reported insider purchase (code P) in the same window. Browse insider activity →

Percentiles describe where a figure sits among industry peers reporting it (100th = highest). They are position within a peer group, not a rating, and not investment advice. Short interest ranking uses days to cover from FINRA Consolidated Short Interest data; FINRA is the owner and source of that data, included at no additional charge.

Institutional ownership

Held by 4 of the superinvestors we track (plus 6 quant / multi-strat books), based on each investor’s most recent 13F; periods vary by investor (newest: Q2 2026).

Conviction investors
4
+6 quant / multi-strat
Initiated / added
5
1 new, 4 added
Reduced / exited
6
5 trimmed, 1 exited
Combined position
$1.71B
reported long value
InvestorAs ofPosition valueSharesChange
D. E. ShawquantQ2 2026$788.7M4.9MReduced
Citadel AdvisorsquantQ2 2026$281.1M1.7MAdded
AQR Capital ManagementquantQ2 2026$262.4M1.6MAdded
Millennium ManagementquantQ2 2026$212.2M1.3MReduced
Point72 Asset ManagementquantQ2 2026$91.6M565.8KNew
Two Sigma InvestmentsquantQ2 2026$61.5M379.6KReduced
Gotham Asset ManagementQ2 2026$8.2M50.8KAdded
Bridgewater AssociatesQ2 2026$2.3M14.1KAdded
Dodge & CoxQ2 2026$1.2M7.6KReduced
ARK Investment ManagementQ2 2026$76,098470Reduced

No longer held by: Renaissance Technologies (as of Q2 2026)

From quarterly Form 13F filings, which can be up to 45 days delayed. Long US-listed positions only: excludes short positions, options, cash, bonds, and non-US holdings, so this is not a manager’s complete portfolio. Counts are of the investors we track, not all institutions. Not investment advice.

Recent insider activity

Non-derivative buys and sells (codes P/S) reported by officers, directors and 10% owners on SEC Form 4.

Buys (90d)
0
code P
Bought (90d)
code P value
Sells (90d)
5
$4.3M
Reported activity
Net selling
by $ value, 90d
Trade dateInsiderTypeSharesPriceValue
2026-08-05
filed 2026-08-06
Chavez Rodriguez Beatriz KarinaGroup PresidentSell3.6K$182.51$663K
2026-07-23
filed 2026-07-24
Banovetz John PatrickExecutive Vice PresidentSell7.9K$170.44$1.3M
2026-07-23
filed 2026-07-24
Reinseth Theresa ESr Vice President & CAOSell924$169.42$157K
2026-07-22
filed 2026-07-23
Rhodes Kevin HEVP, Chief Legal Off & SecretSell7.7K$171.20$1.3M
2026-07-22
filed 2026-07-23
Goralski Christian T JRGroup PresidentSell4.9K$170.46$836K

Reported non-derivative purchases and sales (codes P/S) — which may be open-market or private; excludes option exercises, grants, and shares withheld for taxes. Dates shown are the trade date; a Form 4 can be filed days to years later. A sale can be routine (e.g. a pre-set 10b5-1 plan), so read individual transactions in context. From SEC Form 4. Not investment advice.

Short interest

Total shares sold short as of each twice-monthly FINRA settlement. Rising short interest means more investors are positioned against the stock; days to cover estimates how many trading days of average volume that position represents.

Shares short
9.6M
settled 2026-08-14
Change vs prior
-3.3%
vs previous settlement
Days to cover
3.72
at avg daily volume
Avg daily volume
2.6M
FINRA reported
SettlementShares shortChangeDays to cover
2026-08-149.6M-3.3%3.72
2026-07-319.9M-9.1%2.15
2026-07-1510.9M+11.8%4.34
2026-06-309.8M-16.5%2.32
2026-06-1511.7M+22.3%3.03
2026-05-299.6M+12.3%2.37
2026-05-158.5M+2.1%2.16
2026-04-308.4M+4.8%1.83

Source: FINRA Consolidated Short Interest. FINRA is the owner and source of the FINRA-supplied data, which is included at no additional charge for your own personal or professional use; republishing or redistributing it is not permitted. Settlement dates are shown; FINRA publishes each settlement about nine business days later, so the latest figure can be two to four weeks old. Not presented as a percentage of float. No FINRA endorsement of this product is implied. Not investment advice.

Income statement (as reported)

 FY2025FY2024FY2023FY2022FY2021
Revenue$24.95B$24.57B$24.61B$26.16B$35.35B
Gross profit$9.96B$10.13B$9.63B$10.31B$16.56B
Operating income$4.63B$4.82B$-10.69B$4.37B$7.37B
Net income$3.25B$4.17B$-7.00B$5.78B$5.92B
Diluted EPS$6.00$7.55$-12.63$10.18$10.12

Figures as reported to the SEC. Underlined values link to the filing they came from; dotted values are calculated by us from reported figures; “adj” means restated for a stock split (hover to see the figure as filed). Full details: where the numbers come from.

Balance sheet (as reported)

Figures as reported to the SEC. Underlined values link to the filing they came from; dotted values are calculated by us from reported figures; “adj” means restated for a stock split (hover to see the figure as filed). Full details: where the numbers come from.

Cash flow (as reported)

 FY2025FY2024FY2023FY2022FY2021
Operating cash flow$2.31B$1.82B$6.68B$5.59B$7.45B
Capital expenditure$910.0M$1.18B$1.61B$1.75B$1.60B
Free cash flow$1.40B$638.0M$5.07B$3.84B$5.85B

Figures as reported to the SEC. Underlined values link to the filing they came from; dotted values are calculated by us from reported figures; “adj” means restated for a stock split (hover to see the figure as filed). Full details: where the numbers come from.

Quarterly trend (as reported)

QuarterRevenueRevenue YoYNet incomeDiluted EPS
Q2 FY2026$6.50B2.5%$933.0M$1.78
Q1 FY2026$6.03B1.3%$653.0M$1.23
Q4 FY2025$6.13B2.0%$577.0M$1.07
Q3 FY2025$6.52B3.5%$834.0M$1.55
Q2 FY2025$6.34B1.4%$723.0M$1.34
Q1 FY2025$5.95B-1.0%$1.12B$2.04
Q4 FY2024$6.01B0.1%$728.0M$1.33
Q3 FY2024$6.29B0.4%$1.37B$2.48

Latest 8 reported quarters, from company XBRL filings on SEC EDGAR.

Company facts

ExchangeNYSE
SectorHealthcare
SIC industrySurgical & Medical Instruments & Apparatus
Latest annual periodFY2025 (ended December 31, 2025)
Latest reported quarterQ2 FY2026 (ended June 30, 2026)
Oldest indexed filing2018
SEC CIK66740

Selected SEC filings

10-K2026-02-03
View on EDGAR →
10-K2025-02-05
View on EDGAR →
10-Q2026-07-21
View on EDGAR →
10-Q2026-04-21
View on EDGAR →
10-Q2025-10-21
View on EDGAR →
10-Q2025-07-18
View on EDGAR →
8-K2026-08-19
View on EDGAR →
8-K2026-07-21
View on EDGAR →

Largest medical device peers

All medical device stocksAll Healthcare companies →

MMM head to head

Monitor MMM

Get an alert when 3m files something material, see which superinvestors own it, and ask its filings a question with cited answers.

Monitor MMM free

Includes one free filing-grounded research answer. Or check your whole portfolio, no account needed.

Data sourced from SEC EDGAR. Figures are as-reported and may be unaudited or restated; verify against the source filing before relying on them. Informational only. Not investment advice.